Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China. [electronic resource]
Producer: 20200918Description: 144-156.e1 p. digitalISSN:- 1879-114X
- Aged
- Anticoagulants -- economics
- Atrial Fibrillation -- drug therapy
- China
- Cost-Benefit Analysis
- Dabigatran -- economics
- Embolism -- prevention & control
- Female
- Humans
- Male
- Markov Chains
- Models, Economic
- Quality-Adjusted Life Years
- Rivaroxaban -- economics
- Stroke -- prevention & control
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.